Keenova Highlights XIAFLEX Data and Men's Health Screener at Sexual Medicine Conference

  • Keenova will present data on XIAFLEX for Peyronie's disease at the Sexual Medicine Society of North America annual meeting (Oct. 8-11, 2026).
  • Two presentations focus on clinical studies and real-world outcomes for XIAFLEX in treating Peyronie's disease, including ventral curvature.
  • Third presentation introduces Keenova's Men's Sexual Health Screener, a tool for clinician-patient communication.
  • XIAFLEX is indicated for adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees.

Keenova's presentations at the Sexual Medicine Society of North America annual meeting underscore its focus on men's health, particularly in addressing Peyronie's disease. The company is positioning XIAFLEX as a key nonsurgical treatment option while also introducing tools to facilitate clinician-patient communication. This strategic move aligns with broader industry trends toward personalized and efficient healthcare solutions. The presentations may influence market perception of Keenova's capabilities in the men's health sector.

Clinical Validation
Whether the presented data will strengthen XIAFLEX's position as a nonsurgical treatment option for Peyronie's disease.
Market Adoption
The pace at which Keenova's Men's Sexual Health Screener is adopted by healthcare providers.
Regulatory Dynamics
How the XIAFLEX REMS Program may impact the product's availability and usage.